REGN 1979Alternative Names: REGN1979
Latest Information Update: 18 May 2016
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action CD20 antigen inhibitors; CD3 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute lymphoblastic leukaemia; B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma